Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.53 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.51 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12707445 | 0.88 | KDM5A (0.53) | KDM5AKMT2AMEN1NPC1POLB | |
| SCHEMBL28931514 | 0.86 | MEN1 (0.60) | KDM5ACXCR2KMT2AMEN1NPC1 | |
| SCHEMBL31311054 | 0.85 | KMT2A (0.50) | KMT2AMEN1NPC1POLBRXFP1 | |
| SCHEMBL31311113 | 0.84 | KMT2A (0.49) | KMT2AMEN1NPC1POLBRXFP1 | |
| SCHEMBL31311087 | 0.84 | KMT2A (0.56) | KMT2AMEN1NPC1POLBRXFP1 | |
| SCHEMBL14740985 | 0.83 | HCAR3 (0.61) | KDM5ACXCR2KMT2AMEN1NPC1 | |
| SCHEMBL29692929 | 0.82 | KDM5A (0.59) | KDM5ACXCR2KMT2AMEN1NPC1 | |
| SCHEMBL6359401 | 0.81 | ALB (0.63) | KMT2AMEN1NPC1POLBRXFP1 | |
| SCHEMBL13064964 | 0.80 | TOP1 (0.64) | KDM5ACXCR2KMT2AMEN1NPC1 | |
| SCHEMBL6346687 | 0.78 | ALB (0.60) | KMT2AMEN1RAB9AALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338459-B2 | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | FOLDRX PHARMACEUTICALS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2314584-A1 | 2-(heteroaryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | Foldrx Pharmaceuticals, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20110092545-A1 | Compounds, Compositions and Methods for Stabilizing Transthyretin and Inhibiting Transthyretin Misfolding | FoldRx Pharmaceuticals, Inc., a Massachusetts corporation | 2011-04-21 | — | — | US | disclosed |
| US-7868033-B2 | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | FOLDRX PHARMACEUTICALS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| EP-1768968-A1 | 2-((HETERO) ARYL)-BENZOXAZOLE COMPOUNDS AND DERIVATIVES, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | Foldrx Pharmaceuticals, Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20050282780-A1 | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | FOLDRX PHARMACEUTICALS, LLC | 2005-12-22 | — | — | US | disclosed |
| WO-2005113523-A1 | 2-((HETERO) ARYL)-BENZOXAZOLE COMPOUNDS AND DERIVATIVES, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | FOLDRX PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092545-A1 | Compounds, Compositions and Methods for Stabilizing Transthyretin and Inhibiting Transthyretin Misfolding | TTR, ALB, TTPA | KDM5A 2326/4885CXCR1 4197/4885CXCR2 4567/4885 |
| US-20050282780-A1 | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | TTR, ALB, TTPA | KDM5A 2326/4885CXCR1 4197/4885CXCR2 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.